BC
PTCT icon

Bayforest Capital’s PTC Therapeutics PTCT Stock Holding History

Bayforest Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.9K Buy
+600
New +$43.3K 0.05% 625
2025
Q3 		– Sell
-18,779
Closed -$917K – 886
2025
Q2 		$917K Buy
18,779
+10,626
+130% +$504K 0.4% 51
2025
Q1 		$415K Buy
+8,153
New +$407K 0.18% 205

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Bayforest Capital's PTCT Position: Q2 2026 in Review

Bayforest Capital opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 600 shares worth $48.9K. The stake represents 0.05% of the portfolio and ranks #625 among its holdings. This is a return to the name: Bayforest Capital previously reported a position in PTCT as recently as Q2 2025.

Bayforest Capital first reported a position in PTCT in Q1 2025 and has held it in 3 quarters since. The position peaked at $917K in Q2 2025. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Bayforest Capital held 600 shares of PTC Therapeutics worth $48.9K as of Q2 2026.
  • PTC Therapeutics was a new Bayforest Capital position in Q2 2026.
  • PTC Therapeutics made up 0.05% of Bayforest Capital's portfolio in Q2 2026, its #625 holding.
  • Bayforest Capital first reported a position in PTC Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Bayforest Capital's PTC Therapeutics position peaked at $917K in Q2 2025.
  • 383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.